20 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
whose infection source was urinary tract, 68% for patients whose infection source was community-acquired pneumonia, and 36% for patients whose
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
was urinary tract (UTI), 68% for patients whose infection source was community - acquired pneumonia, and 36% for patients whose infection source
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
12 Sep 22
Report of Foreign Private Issuer
8:02am
to discussing our findings with the medical community at this year’s congress.”
Oren Hershkovitz, Ph.D., Chief Executive Officer of Enlivex
424B5
x7sp 45p3fb0
3 Mar 20
Prospectus supplement for primary offering
5:13pm
424B5
hi12iyt85
26 Feb 20
Prospectus supplement for primary offering
8:23am
20-F/A
x1y4mdcgjxuznw
23 Jan 20
Annual report (foreign) (amended)
4:31pm
424B3
3msoidx 4pygya
10 Jul 19
Prospectus supplement
8:18am
F-3
m254g57s
28 Jun 19
Shelf registration (foreign)
9:48am
6-K
EX-99.1
hjy vqoeuyv2p
27 Oct 15
Current report (foreign)
12:00am
20-F
nz1yvjenr3
31 Mar 15
Annual report (foreign)
12:00am
424B4
1hx006
31 Jul 14
Prospectus supplement with pricing info
12:00am
F-1/A
lq0v jehwxl
8 Jul 14
Registration statement (foreign) (amended)
12:00am
- Prev
- 1
- Next